数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

股本结构

单位:万股
公告日期 2021-01-13 2020-12-31 2020-11-06 2020-11-06 2020-09-11 2020-09-11
证券总股本 948.32 799.37 4796.24 4770.48 4796.82 4797.91
普通股本 948.32 799.37 4796.24 4770.48 4796.82 4797.91
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2021-01-07 2021-01-04 2020-10-30 2020-09-30 2020-09-09 2020-07-22
注释:中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本(万股) 变动后优先股(万股) 变动原因 变动日期
2021-01-13 948.32 未披露 定期报告 2021-01-07
2020-12-31 799.37 未披露
更多>>
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-adjusted basis at the market open on January 4, 2021.
2021-01-04
2020-11-06 4796.24 未披露 定期报告 2020-10-30
2020-11-06 4770.48 未披露 定期报告 2020-09-30
2020-09-11 4796.82 未披露 定期报告 2020-09-09
2020-09-11 4797.91 未披露 定期报告 2020-07-22
2020-08-10 4770.48 未披露 定期报告 2020-06-30
2020-06-29 4798.11 未披露 定期报告 2020-06-26
2020-07-06 4798.11 未披露 定期报告 2020-06-19
2020-05-08 4798.45 未披露 定期报告 2020-05-04
2020-04-28 4798.53 未披露 定期报告 2020-04-20
2020-05-08 4770.48 未披露
更多>>
From December 31, 2019 to March 31, 2020 Compensation expense for issuance of restricted stock to employees
2020-03-31
2020-04-28 4799.18 未披露 定期报告 2020-03-15
2020-02-28 4799.70 未披露 定期报告 2020-02-20
2020-02-28 4770.11 未披露
更多>>
From December 31, 2018 to December 31, 2019 Compensation expense for issuance of restricted stock to employees Exercise of stock options Purchase of Treasury Stock
2019-12-31
2019-11-07 4803.02 未披露 定期报告 2019-10-31
2019-11-07 4751.06 未披露
更多>>
From June 30, 2019 to September 30, 2019 Compensation expense for issuance of restricted stock to employees
2019-09-30
2019-08-07 4810.80 未披露 定期报告 2019-07-31
2019-08-07 4750.56 未披露
更多>>
From March 31, 2019 to June 30, 2019 Compensation expense for issuance of restricted stock to employees Adjustments to Treasury Stock Purchase of Treasury Stock
2019-06-30
2019-05-07 4812.97 未披露 定期报告 2019-05-01
2019-04-26 4809.96 未披露 定期报告 2019-04-22
2019-05-07 4747.16 未披露
更多>>
from December 31, 2018 to March 31, 2019 Compensation expense for issuance of restricted stock to employees Exercise of stock options Purchase of Treasury Stock
2019-03-31
2019-04-26 4808.70 未披露 定期报告 2019-03-15
2019-02-27 4763.34 未披露 定期报告 2019-02-20
2019-02-27 4742.08 未披露
更多>>
from December 31, 2017 to December 31, 2018 Compensation expense for issuance of restricted stock to employees Exercise of stock options Purchase of Treasury Stock
2018-12-31
2018-11-06 4755.83 未披露 定期报告 2018-10-31
2018-11-06 4723.10 未披露 定期报告 2018-09-30
2018-08-08 4748.38 未披露 定期报告 2018-07-31
2018-08-08 4714.38 未披露 定期报告 2018-06-30
2018-05-09 4706.65 未披露 定期报告 2018-05-07
2018-04-27 4705.98 未披露 定期报告 2018-04-25
2018-05-09 4666.16 未披露 定期报告 2018-03-31
2018-04-27 4700.14 未披露 定期报告 2018-03-15
2018-03-01 4691.38 未披露 定期报告 2018-02-20
2018-03-01 4642.53 未披露
更多>>
from December 31, 2016 to December 31, 2017 Compensation expense for issuance of restricted stock to employees Exercise of stock options
2017-12-31
2017-11-07 4674.72 未披露 定期报告 2017-10-31
2017-11-07 4670.43 未披露 定期报告 2017-09-30
2017-08-08 4665.07 未披露 定期报告 2017-07-31
2017-08-08 4664.08 未披露 定期报告 2017-06-30
2017-05-09 4665.94 未披露 定期报告 2017-04-30
2017-05-09 4675.82 未披露 定期报告 2017-03-31
2017-04-21 4676.04 未披露 定期报告 2017-03-15
2017-02-27 4640.79 未披露 定期报告 2017-02-17
2017-02-27 4566.76 未披露
更多>>
from December 31, 2015 to December 31, 2016 Compensation expense for issuance of restricted stock to employees Exercise of stock options Private placement, net of issuance costs
2016-12-31
2016-11-07 4611.43 未披露 定期报告 2016-10-31
2016-11-07 4613.25 未披露 定期报告 2016-09-30
2016-08-04 4613.99 未披露 定期报告 2016-07-29
2016-08-04 4609.09 未披露 定期报告 2016-06-30
2016-05-06 4606.73 未披露 定期报告 2016-04-30
2016-04-29 4595.73 未披露 定期报告 2016-04-11
2016-05-06 4596.25 未披露 定期报告 2016-03-31
2016-02-29 4574.93 未披露 定期报告 2016-02-17
2016-02-29 4298.70 未披露
更多>>
from December 31, 2014 to December 31, 2015 Compensation expense for issuance of restricted stock to employees Exercise of stock options
2015-12-31
2015-11-09 4315.54 未披露 定期报告 2015-10-31
2015-11-09 4287.67 未披露 定期报告 2015-09-30
2015-08-07 4284.63 未披露 定期报告 2015-07-31
2015-08-07 4281.74 未披露 定期报告 2015-06-30
2015-05-08 4279.09 未披露 定期报告 2015-04-30
2015-04-30 4279.72 未披露 定期报告 2015-04-13
2015-05-08 4278.56 未披露 定期报告 2015-03-31
2015-02-27 4257.54 未披露 定期报告 2015-02-17
2015-02-27 4187.14 未披露
更多>>
from December 31, 2013 to December 31, 2014 Compensation expense for issuance of restricted stock to employees Exercise of stock options
2014-12-31
2014-11-07 4194.80 未披露 定期报告 2014-10-31
2014-11-07 4122.42 未披露 定期报告 2014-09-30
2014-08-07 4174.49 未披露 定期报告 2014-07-31
2014-08-07 4106.05 未披露 定期报告 2014-06-30
2014-05-09 4164.59 未披露 定期报告 2014-04-30
2014-04-25 4165.36 未披露 定期报告 2014-04-08
2014-05-09 4102.81 未披露 定期报告 2014-03-31
2014-03-03 4131.08 未披露 定期报告 2014-02-14
2014-03-03 4088.39 未披露
更多>>
From December 31,2012 to December 31,2013 Compensation expense for issuance of restricted stock to employees Exercise of stock options
2013-12-31
2013-11-07 4127.46 未披露 定期报告 2013-10-31
2013-11-07 4061.12 未披露 定期报告 2013-09-30
2013-08-08 4069.35 未披露 定期报告 2013-07-31
2013-08-08 4004.21 未披露 定期报告 2013-06-30
2013-05-10 4056.61 未披露 定期报告 2013-04-30
2013-04-19 4054.70 未披露 定期报告 2013-04-02
2013-05-10 3988.10 未披露 定期报告 2013-03-31
2013-02-28 4028.01 未披露 定期报告 2013-02-15
2013-02-28 3979.21 未披露
更多>>
from December 31, 2011 to December 31, 2012 Compensation expense for issuance of restricted stock to employees Exercise of stock options
2012-12-31
2012-11-08 4015.77 未披露 定期报告 2012-10-31
2012-11-08 3948.17 未披露 定期报告 2012-09-30
2012-08-08 4009.33 未披露 定期报告 2012-07-31
2012-08-08 3945.47 未披露 定期报告 2012-06-30
2012-05-09 4009.62 未披露 定期报告 2012-04-30
2012-05-09 3941.04 未披露 定期报告 2012-03-31
2012-02-28 3970.11 未披露 定期报告 2012-02-15
2012-02-28 3931.61 未披露
更多>>
FROM December 31, 2010 TO December 31, 2011 Compensation expense for issuance of restricted stock to employees Exercise of stock options
2011-12-31
2011-11-07 3966.75 未披露 定期报告 2011-10-31
2011-11-07 3910.89 未披露 定期报告 2011-09-30
2011-08-08 3965.77 未披露 定期报告 2011-07-31
2011-08-08 3909.44 未披露 定期报告 2011-06-30
2011-05-09 3946.20 未披露 定期报告 2011-04-30
2011-05-09 3879.58 未披露 定期报告 2011-03-31
2011-03-01 3910.12 未披露 定期报告 2011-02-17
2011-03-01 3876.70 未披露
更多>>
Compensation expense for issuance of restricted stock to employees Exercise of stock options
2010-12-31
2010-11-09 3907.97 未披露 定期报告 2010-10-31
2010-11-09 3856.84 未披露
更多>>
Vested and expected to vest at September 30, 2010 Vested and exercisable at September 30, 2010
2010-09-30
2010-08-09 3887.57 未披露 定期报告 2010-07-31
2010-08-09 3835.25 未披露
更多>>
Vested and expected to vest at June 30, 2010 Vested and exercisable at June 30, 2010
2010-06-30
2010-05-10 3872.11 未披露 定期报告 2010-04-30
2010-05-10 3825.17 未披露
更多>>
Vested and expected to vest at March 31, 2010 Vested and exercisable at March 31, 2010
2010-03-31
2010-02-26 3816.13 未披露 定期报告 2010-02-19
2010-02-26 3793.51 未披露
更多>>
from December 31, 2008 to December 31, 2009 Compensation expense for issuance of restricted stock to employees Exercise of stock options
2009-12-31
2009-03-02 3777.47 未披露 定期报告 2009-02-13
2009-03-02 3761.34 未披露
更多>>
from December 31, 2007 to December 31, 2008 Compensation expense for issuance of restricted stock to employees Exercise of stock options Common stock issued pursuant to follow-on offerings, net of offering costs of $9,686,600 Stock issued pursuant to NRI asset acquisition
2008-12-31
2008-03-14 3245.84 未披露 定期报告 2008-02-22
2008-03-14 2857.47 未披露
更多>>
from December 31, 2006 to December 31, 2007 Compensation expense for issuance of restricted stock to employees Exercise of stock options Common stock issued pursuant to follow-on offering, net of offering costs of $5,290,961 Common stock issued pursuant to exercise of warrants
2007-12-31
2007-05-08 2412.50 未披露 定期报告 2007-03-01
2007-03-26 2371.64 未披露 定期报告 2007-02-28
2007-03-26 2365.78 未披露
更多>>
from December 31, 2005 to December 31, 2006 Conversion convertible preferred stock to common stock Common stock issued pursuant to IPO, net of offering costs of $4,994,373 Common stock issued pursuant to private placement, net of offering costs of $1,718,584 Common stock issued pursuant to cashless exercise of warrants Common stock issued pursuant to conversion of convertible
2006-12-31
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-adjusted basis at the market open on January 4, 2021.
From December 31, 2019 to March 31, 2020 Compensation expense for issuance of restricted stock to employees
From December 31, 2018 to December 31, 2019 Compensation expense for issuance of restricted stock to employees Exercise of stock options Purchase of Treasury Stock
From June 30, 2019 to September 30, 2019 Compensation expense for issuance of restricted stock to employees
From March 31, 2019 to June 30, 2019 Compensation expense for issuance of restricted stock to employees Adjustments to Treasury Stock Purchase of Treasury Stock
from December 31, 2018 to March 31, 2019 Compensation expense for issuance of restricted stock to employees Exercise of stock options Purchase of Treasury Stock
from December 31, 2017 to December 31, 2018 Compensation expense for issuance of restricted stock to employees Exercise of stock options Purchase of Treasury Stock
from December 31, 2016 to December 31, 2017 Compensation expense for issuance of restricted stock to employees Exercise of stock options
from December 31, 2015 to December 31, 2016 Compensation expense for issuance of restricted stock to employees Exercise of stock options Private placement, net of issuance costs
from December 31, 2014 to December 31, 2015 Compensation expense for issuance of restricted stock to employees Exercise of stock options
from December 31, 2013 to December 31, 2014 Compensation expense for issuance of restricted stock to employees Exercise of stock options
From December 31,2012 to December 31,2013 Compensation expense for issuance of restricted stock to employees Exercise of stock options
from December 31, 2011 to December 31, 2012 Compensation expense for issuance of restricted stock to employees Exercise of stock options
FROM December 31, 2010 TO December 31, 2011 Compensation expense for issuance of restricted stock to employees Exercise of stock options
Compensation expense for issuance of restricted stock to employees Exercise of stock options
Vested and expected to vest at September 30, 2010 Vested and exercisable at September 30, 2010
Vested and expected to vest at June 30, 2010 Vested and exercisable at June 30, 2010
Vested and expected to vest at March 31, 2010 Vested and exercisable at March 31, 2010
from December 31, 2008 to December 31, 2009 Compensation expense for issuance of restricted stock to employees Exercise of stock options
from December 31, 2007 to December 31, 2008 Compensation expense for issuance of restricted stock to employees Exercise of stock options Common stock issued pursuant to follow-on offerings, net of offering costs of $9,686,600 Stock issued pursuant to NRI asset acquisition
from December 31, 2006 to December 31, 2007 Compensation expense for issuance of restricted stock to employees Exercise of stock options Common stock issued pursuant to follow-on offering, net of offering costs of $5,290,961 Common stock issued pursuant to exercise of warrants
from December 31, 2005 to December 31, 2006 Conversion convertible preferred stock to common stock Common stock issued pursuant to IPO, net of offering costs of $4,994,373 Common stock issued pursuant to private placement, net of offering costs of $1,718,584 Common stock issued pursuant to cashless exercise of warrants Common stock issued pursuant to conversion of convertible